Evaluation of Safety,Tolerability and Pharmacokinetic Characteristics of CG400549 in Healthy Volunteers.

Trial Profile

Evaluation of Safety,Tolerability and Pharmacokinetic Characteristics of CG400549 in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2013

At a glance

  • Drugs CG 400549 (Primary)
  • Indications Methicillin-resistant Staphylococcus aureus infections; Staphylococcal infections; Vancomycin-resistant Staphylococcus aureus infections
  • Focus Adverse reactions
  • Sponsors CrystalGenomics
  • Most Recent Events

    • 10 May 2010 According to a CrystalGenomics media release, the company has succesfully completed the single ascending dose Phase I clinical trial for CG400549.
    • 13 Mar 2010 Actual initiation date (Oct 2009), planned no of patients [18], official title added as reported by ClinicalTrials.gov.
    • 13 Mar 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top